BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Releases Quarterly Earnings Results, Beats Expectations By $0.18 EPS

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) announced its quarterly earnings data on Thursday. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.18, Zacks reports.

BridgeBio Oncology Therapeutics Trading Up 5.4%

Shares of BBOT opened at $10.42 on Friday. BridgeBio Oncology Therapeutics has a 12-month low of $8.50 and a 12-month high of $14.87. The firm has a market capitalization of $833.50 million, a P/E ratio of -10.12 and a beta of 0.28.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC bought a new position in shares of BridgeBio Oncology Therapeutics in the fourth quarter valued at $63,000. Persistent Asset Partners Ltd bought a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth about $107,000. Squarepoint Ops LLC acquired a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter worth about $144,000. Quadrature Capital Ltd bought a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $162,000. Finally, XTX Topco Ltd boosted its stake in BridgeBio Oncology Therapeutics by 22.4% during the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after purchasing an additional 5,249 shares during the last quarter. Institutional investors and hedge funds own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics News Roundup

Here are the key news stories impacting BridgeBio Oncology Therapeutics this week:

• Positive Sentiment: Publication of peer?reviewed preclinical data for BBO?11818 (panKRAS) in Cancer Discovery, highlighting potent activity against KRAS G12D/V/C, ON/OFF state inhibition, strong selectivity, and combination potential — adds scientific validation to BBOT’s lead KRAS program. Read More.
• Positive Sentiment: Early Phase 1 KONQUER?101 clinical signals for BBO?11818 (including a reported confirmed partial response in PDAC and encouraging anti?tumor activity) support near?term clinical upside and future data readouts expected H2 2026. Read More.
• Positive Sentiment: Quarterly results: BBOT reported EPS of ($0.49) vs. consensus ($0.67), beating estimates — a near?term financial surprise that can reduce investor uncertainty around cash?burn guidance and valuation assumptions. Read More.
• Positive Sentiment: HC Wainwright raised its price target to $29 and reiterated a Buy, signaling stronger sell?side conviction and providing a high upside reference for investors. Read More.
• Neutral Sentiment: Corporate update/Q4 & FY?2025 filing recap: BBOT summarized clinical progress across three RAS?pathway programs (BBO?8520, BBO?11818, BBO?10203) and reiterated combination strategies — useful context but largely already reflected in recent releases. Read More.
• Neutral Sentiment: Short?interest data reported anomalies (0 shares / NaN change) for early March — appears to be a data glitch and unlikely to meaningfully explain price moves.
• Negative Sentiment: Key risk: important clinical and regulatory milestones (additional BBO?11818 data and combination studies) are scheduled for H2 2026 — the multi?quarter timeline sustains execution risk and valuation uncertainty until those readouts.

Analyst Ratings Changes

Several brokerages recently issued reports on BBOT. Raymond James Financial raised shares of BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research note on Friday, January 9th. HC Wainwright lifted their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings initiated coverage on shares of BridgeBio Oncology Therapeutics in a report on Wednesday, January 14th. They set a “sell (d+)” rating on the stock. Finally, Stifel Nicolaus initiated coverage on BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They issued a “buy” rating and a $23.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $26.00.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.